Straits Times Index
3,240.58 +49.87 (+1.56%) S&P 500
3,901.36 +0.57 (+0.01%) Dow
31,261.90 +8.77 (+0.03%) Nasdaq
11,354.62 -33.88 (-0.30%) BTC-USD
29,783.93 +222.80 (+0.75%) CMC Crypto 200
650.34 -23.03 (-3.42%)
Seagen Inc. (SGEN)
After hours:
| Previous close | 142.63 |
| Open | 144.20 |
| Bid | 138.97 x 800 |
| Ask | 140.66 x 1400 |
| Day's range | 136.11 - 144.46 |
| 52-week range | 105.43 - 192.79 |
| Volume | |
| Avg. volume | 1,072,248 |
| Market cap | 25.704B |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
BOTHELL, Wash., May 16, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen’s Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found.
- Business Wire
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
BOTHELL, Wash., May 09, 2022--The Board of Directors of Seagen Inc. (Nasdaq: SGEN) today announced that President, CEO and Chairman Clay Siegall, Ph.D. is on a leave of absence. The company is aware of an alleged incident of domestic violence that occurred recently at Dr. Siegall’s home. Dr. Siegall has denied these allegations and has informed the company that he is engaged in a divorce. The Board of Directors has formed a committee of independent directors and is conducting a thorough investig
- Business Wire
Seagen Reports First Quarter 2022 Financial Results
BOTHELL, Wash., April 28, 2022--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline.
